Durable Responses and Stable Disease in Multiple ATM-Altered Advanced Cancers

In this MEDtalk, Martin Højgaard presents the efficacy of camonsertib monotherapy in the subset of patients with advanced cancers harboring ataxia telangiectasia-mutated (ATM) kinase loss-of-function (LoF) (TRESR study). Camonsertib is a selective oral inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with demonstrated efficacy in tumors with DNA damage response gene deficiencies. The study shows that patients with bi-allelic ATM loss had better clinical outcomes, with a 48% clinical benefit rate and some long-lasting responses.
Bi-allelic inactivation, particularly in germline mutations, was a key factor in positive responses.